State Department gets new biotech diplomat—but no public oversight
H.R. 9755 — Biotechnology Diplomacy Leadership Act of 2026 · Filed by Rich McCormick (R-GA) · 1 cosponsor · Introduced Jul 16, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a new position at the State Department called the Senior Biotechnology Official, to be appointed within 90 days. The official will coordinate U.S. diplomatic efforts on biotechnology, including supply-chain security, international research partnerships, data-sharing agreements, and capacity-building with allied nations—essentially making biotechnology a formal diplomatic priority alongside traditional foreign policy.
Why we flagged it
The bill's core function is to establish a new State Department position and coordination mechanism for biotechnology diplomacy. It is not a regulatory change, appropriation, or substantive policy—it is an organizational/institutional measure that creates a new diplomatic role and reporting structure.
What the text implies
- The bill grants the Secretary of State broad discretion to assign 'any other duties' to the new official, creating potential for mission creep or undefined responsibilities without further congressional oversight.
- The phrase 'securing biotechnology supply chains' and 'advancing commercial and regulatory diplomacy' could be interpreted to prioritize pharmaceutical industry market access and IP protection over public-health equity or pandemic preparedness.
The full analysis lists 5 implications of this text.
Who stands to gain
pharmaceutical companies (BMY, PFE, JNJ, GH, DVA); biotechnology firms seeking international market access; U.S. biotech exporters and IP holders